Pure Financial Advisors’s Evoke Pharma EVOK Stock Holding History

Pure Financial Advisors’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-123	Closed	-$9K	–	240
2022 Q1	$9K	Hold	123	–	–	﹤0.01%	222
2021 Q4	$10K	Hold	123	–	–	﹤0.01%	211
2021 Q3	$23K	Hold	123	–	–	﹤0.01%	196
2021 Q2	$24K	Hold	123	–	–	﹤0.01%	197
2021 Q1	$32K	Buy	+123	New	+$49.2K	﹤0.01%	183

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Pure Financial Advisors's EVOK Position: Q2 2022 in Review

Pure Financial Advisors sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 123 shares — an estimated $9K sold.

Pure Financial Advisors first reported a position in EVOK in Q1 2021 and held it in 5 quarters. The position peaked at $32K in Q1 2021. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

Pure Financial Advisors reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
Pure Financial Advisors sold 123 Evoke Pharma shares in Q2 2022, an estimated $9K.
Pure Financial Advisors first reported a position in Evoke Pharma in Q1 2021 and held it in 5 quarters.
Pure Financial Advisors's Evoke Pharma position peaked at $32K in Q1 2021.
12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Pure Financial Advisors's 13F filing for Q2 2022, filed 8 Jul 2022.